JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2124580, encodeId=a9f0212458035, content=可以共同通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7d6401298, createdName=ms2000000538736621, createdTime=Sun Apr 09 13:44:25 CST 2023, time=2023-04-09, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1238888, encodeId=c680123888819, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;生信 经验分享：7.10投稿 7.11修改格式 7.11 再次提交投稿 7.12 分配编辑 7.15 审稿人审稿 8.15 文章接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba432251336, createdName=poppin kitty, createdTime=Mon Aug 15 21:55:12 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103332, encodeId=e9b92103332e5, content=审稿速度:2.0 经验分享：10 reviewers invited 一个月了，可以催稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94318203192, createdName=ms6000001327920543, createdTime=Tue Nov 29 16:42:06 CST 2022, time=2022-11-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1242895, encodeId=c45212428954e, content=现在还收SEER挖掘的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220130/d287bef646804051826c653c20ade5c5/3189bee4394c4a70a2c21f4e2d6b8f13.jpg, createdBy=cb882558554, createdName=cmj544, createdTime=Sat Sep 03 01:41:42 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123298, encodeId=2f2121232987e, content=请教一下大家，大家的审稿人一般都是几个呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=ms1000000056011696, createdTime=Sun Apr 02 18:55:29 CST 2023, time=2023-04-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103169, encodeId=c26a21031699c, content=审稿速度:1.0 经验分享：请问大家接收之后多久见刊的呀？接收之后通讯作者一直没有收到确认proof的通知，一个多月了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf758287370, createdName=ms1000000773147608, createdTime=Mon Nov 28 21:35:40 CST 2022, time=2022-11-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1063656, encodeId=e0ab10636562a, content=昨日凌晨文章接受，因为杂志效率高所以投了，没上5分是个遗憾，写一下时间线吧，贡大家参考 临床回顾研究，头颈肿瘤主编和副编效率一流，审稿人效率也是见过最快的，初审14天，二审7天 2021-8-27 new submission 2021-9-20 minor revisions 2021-10-11 Revision Submitted 2021-10-24 reviews completed 2021-10-24 editor assigned 2021-10-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74db5149632, createdName=1469323em90暂无昵称, createdTime=Mon Oct 25 07:27:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121859, encodeId=e14221218596e, content=请问这个杂志要求查重率在多少以下呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87d45469232, createdName=ms4000000806385083, createdTime=Sun Mar 26 10:34:53 CST 2023, time=2023-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2107899, encodeId=d0cf210e8998b, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：11.10投稿 11.13送审 11.26 2个审稿人接收，1个审稿人意见已回 12.1 第2个审稿人意见回，等待编辑决定 12.7 返修 12.16 提交 12.20 邀请一个审稿人 12.22 收到审稿人报告 12.24 接收 第一次投这个杂志，过程愉快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221012/58d49d92e28d4e819acde854b28c54f3/2d209f1b3c1c49a69e36f6b2ebb7804f.jpeg, createdBy=b5d25455370, createdName=ms1000001786385695, createdTime=Wed Dec 28 20:31:08 CST 2022, time=2022-12-28, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1081922, encodeId=0366108192243, content=偏重的研究方向：肿瘤 经验分享：我的文章13号接收的，回来看评论，很多朋友都在问参考文献格式怎么下，说实话，到现在文章被接收我都不知道哪里下，我当时投稿的时候也是找了半天没找到，后来索性找了个施普林格旗下比较类似的文献格式，然后用endnote编辑成JOCR这个样子的，然后投稿了，到现在接收了也没有什么问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5bc5555629, createdName=解忧, createdTime=Sun Dec 19 22:32:54 CST 2021, time=2021-12-19, status=1, ipAttribution=)]

2023-04-09 ms2000000538736621 来自安徽省

可以共同通讯吗

25 0

[GetPortalCommentsPageByObjectIdResponse(id=2124580, encodeId=a9f0212458035, content=可以共同通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7d6401298, createdName=ms2000000538736621, createdTime=Sun Apr 09 13:44:25 CST 2023, time=2023-04-09, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1238888, encodeId=c680123888819, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;生信 经验分享：7.10投稿 7.11修改格式 7.11 再次提交投稿 7.12 分配编辑 7.15 审稿人审稿 8.15 文章接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba432251336, createdName=poppin kitty, createdTime=Mon Aug 15 21:55:12 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103332, encodeId=e9b92103332e5, content=审稿速度:2.0 经验分享：10 reviewers invited 一个月了，可以催稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94318203192, createdName=ms6000001327920543, createdTime=Tue Nov 29 16:42:06 CST 2022, time=2022-11-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1242895, encodeId=c45212428954e, content=现在还收SEER挖掘的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220130/d287bef646804051826c653c20ade5c5/3189bee4394c4a70a2c21f4e2d6b8f13.jpg, createdBy=cb882558554, createdName=cmj544, createdTime=Sat Sep 03 01:41:42 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123298, encodeId=2f2121232987e, content=请教一下大家，大家的审稿人一般都是几个呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=ms1000000056011696, createdTime=Sun Apr 02 18:55:29 CST 2023, time=2023-04-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103169, encodeId=c26a21031699c, content=审稿速度:1.0 经验分享：请问大家接收之后多久见刊的呀？接收之后通讯作者一直没有收到确认proof的通知，一个多月了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf758287370, createdName=ms1000000773147608, createdTime=Mon Nov 28 21:35:40 CST 2022, time=2022-11-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1063656, encodeId=e0ab10636562a, content=昨日凌晨文章接受，因为杂志效率高所以投了，没上5分是个遗憾，写一下时间线吧，贡大家参考 临床回顾研究，头颈肿瘤主编和副编效率一流，审稿人效率也是见过最快的，初审14天，二审7天 2021-8-27 new submission 2021-9-20 minor revisions 2021-10-11 Revision Submitted 2021-10-24 reviews completed 2021-10-24 editor assigned 2021-10-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74db5149632, createdName=1469323em90暂无昵称, createdTime=Mon Oct 25 07:27:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121859, encodeId=e14221218596e, content=请问这个杂志要求查重率在多少以下呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87d45469232, createdName=ms4000000806385083, createdTime=Sun Mar 26 10:34:53 CST 2023, time=2023-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2107899, encodeId=d0cf210e8998b, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：11.10投稿 11.13送审 11.26 2个审稿人接收，1个审稿人意见已回 12.1 第2个审稿人意见回，等待编辑决定 12.7 返修 12.16 提交 12.20 邀请一个审稿人 12.22 收到审稿人报告 12.24 接收 第一次投这个杂志，过程愉快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221012/58d49d92e28d4e819acde854b28c54f3/2d209f1b3c1c49a69e36f6b2ebb7804f.jpeg, createdBy=b5d25455370, createdName=ms1000001786385695, createdTime=Wed Dec 28 20:31:08 CST 2022, time=2022-12-28, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1081922, encodeId=0366108192243, content=偏重的研究方向：肿瘤 经验分享：我的文章13号接收的，回来看评论，很多朋友都在问参考文献格式怎么下，说实话，到现在文章被接收我都不知道哪里下，我当时投稿的时候也是找了半天没找到，后来索性找了个施普林格旗下比较类似的文献格式，然后用endnote编辑成JOCR这个样子的，然后投稿了，到现在接收了也没有什么问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5bc5555629, createdName=解忧, createdTime=Sun Dec 19 22:32:54 CST 2021, time=2021-12-19, status=1, ipAttribution=)]

2022-08-15 poppin kitty

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤;生信
经验分享：7.10投稿
7.11修改格式
7.11 再次提交投稿
7.12 分配编辑
7.15 审稿人审稿
8.15 文章接收

39 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2124580, encodeId=a9f0212458035, content=可以共同通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7d6401298, createdName=ms2000000538736621, createdTime=Sun Apr 09 13:44:25 CST 2023, time=2023-04-09, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1238888, encodeId=c680123888819, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;生信 经验分享：7.10投稿 7.11修改格式 7.11 再次提交投稿 7.12 分配编辑 7.15 审稿人审稿 8.15 文章接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba432251336, createdName=poppin kitty, createdTime=Mon Aug 15 21:55:12 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103332, encodeId=e9b92103332e5, content=审稿速度:2.0 经验分享：10 reviewers invited 一个月了，可以催稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94318203192, createdName=ms6000001327920543, createdTime=Tue Nov 29 16:42:06 CST 2022, time=2022-11-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1242895, encodeId=c45212428954e, content=现在还收SEER挖掘的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220130/d287bef646804051826c653c20ade5c5/3189bee4394c4a70a2c21f4e2d6b8f13.jpg, createdBy=cb882558554, createdName=cmj544, createdTime=Sat Sep 03 01:41:42 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123298, encodeId=2f2121232987e, content=请教一下大家，大家的审稿人一般都是几个呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=ms1000000056011696, createdTime=Sun Apr 02 18:55:29 CST 2023, time=2023-04-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103169, encodeId=c26a21031699c, content=审稿速度:1.0 经验分享：请问大家接收之后多久见刊的呀？接收之后通讯作者一直没有收到确认proof的通知，一个多月了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf758287370, createdName=ms1000000773147608, createdTime=Mon Nov 28 21:35:40 CST 2022, time=2022-11-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1063656, encodeId=e0ab10636562a, content=昨日凌晨文章接受，因为杂志效率高所以投了，没上5分是个遗憾，写一下时间线吧，贡大家参考 临床回顾研究，头颈肿瘤主编和副编效率一流，审稿人效率也是见过最快的，初审14天，二审7天 2021-8-27 new submission 2021-9-20 minor revisions 2021-10-11 Revision Submitted 2021-10-24 reviews completed 2021-10-24 editor assigned 2021-10-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74db5149632, createdName=1469323em90暂无昵称, createdTime=Mon Oct 25 07:27:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121859, encodeId=e14221218596e, content=请问这个杂志要求查重率在多少以下呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87d45469232, createdName=ms4000000806385083, createdTime=Sun Mar 26 10:34:53 CST 2023, time=2023-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2107899, encodeId=d0cf210e8998b, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：11.10投稿 11.13送审 11.26 2个审稿人接收，1个审稿人意见已回 12.1 第2个审稿人意见回，等待编辑决定 12.7 返修 12.16 提交 12.20 邀请一个审稿人 12.22 收到审稿人报告 12.24 接收 第一次投这个杂志，过程愉快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221012/58d49d92e28d4e819acde854b28c54f3/2d209f1b3c1c49a69e36f6b2ebb7804f.jpeg, createdBy=b5d25455370, createdName=ms1000001786385695, createdTime=Wed Dec 28 20:31:08 CST 2022, time=2022-12-28, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1081922, encodeId=0366108192243, content=偏重的研究方向：肿瘤 经验分享：我的文章13号接收的，回来看评论，很多朋友都在问参考文献格式怎么下，说实话，到现在文章被接收我都不知道哪里下，我当时投稿的时候也是找了半天没找到，后来索性找了个施普林格旗下比较类似的文献格式，然后用endnote编辑成JOCR这个样子的，然后投稿了，到现在接收了也没有什么问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5bc5555629, createdName=解忧, createdTime=Sun Dec 19 22:32:54 CST 2021, time=2021-12-19, status=1, ipAttribution=)]

2022-11-29 ms6000001327920543 来自广东省

审稿速度:2.0
经验分享：10 reviewers invited 一个月了，可以催稿吗？

37 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2124580, encodeId=a9f0212458035, content=可以共同通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7d6401298, createdName=ms2000000538736621, createdTime=Sun Apr 09 13:44:25 CST 2023, time=2023-04-09, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1238888, encodeId=c680123888819, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;生信 经验分享：7.10投稿 7.11修改格式 7.11 再次提交投稿 7.12 分配编辑 7.15 审稿人审稿 8.15 文章接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba432251336, createdName=poppin kitty, createdTime=Mon Aug 15 21:55:12 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103332, encodeId=e9b92103332e5, content=审稿速度:2.0 经验分享：10 reviewers invited 一个月了，可以催稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94318203192, createdName=ms6000001327920543, createdTime=Tue Nov 29 16:42:06 CST 2022, time=2022-11-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1242895, encodeId=c45212428954e, content=现在还收SEER挖掘的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220130/d287bef646804051826c653c20ade5c5/3189bee4394c4a70a2c21f4e2d6b8f13.jpg, createdBy=cb882558554, createdName=cmj544, createdTime=Sat Sep 03 01:41:42 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123298, encodeId=2f2121232987e, content=请教一下大家，大家的审稿人一般都是几个呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=ms1000000056011696, createdTime=Sun Apr 02 18:55:29 CST 2023, time=2023-04-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103169, encodeId=c26a21031699c, content=审稿速度:1.0 经验分享：请问大家接收之后多久见刊的呀？接收之后通讯作者一直没有收到确认proof的通知，一个多月了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf758287370, createdName=ms1000000773147608, createdTime=Mon Nov 28 21:35:40 CST 2022, time=2022-11-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1063656, encodeId=e0ab10636562a, content=昨日凌晨文章接受，因为杂志效率高所以投了，没上5分是个遗憾，写一下时间线吧，贡大家参考 临床回顾研究，头颈肿瘤主编和副编效率一流，审稿人效率也是见过最快的，初审14天，二审7天 2021-8-27 new submission 2021-9-20 minor revisions 2021-10-11 Revision Submitted 2021-10-24 reviews completed 2021-10-24 editor assigned 2021-10-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74db5149632, createdName=1469323em90暂无昵称, createdTime=Mon Oct 25 07:27:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121859, encodeId=e14221218596e, content=请问这个杂志要求查重率在多少以下呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87d45469232, createdName=ms4000000806385083, createdTime=Sun Mar 26 10:34:53 CST 2023, time=2023-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2107899, encodeId=d0cf210e8998b, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：11.10投稿 11.13送审 11.26 2个审稿人接收，1个审稿人意见已回 12.1 第2个审稿人意见回，等待编辑决定 12.7 返修 12.16 提交 12.20 邀请一个审稿人 12.22 收到审稿人报告 12.24 接收 第一次投这个杂志，过程愉快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221012/58d49d92e28d4e819acde854b28c54f3/2d209f1b3c1c49a69e36f6b2ebb7804f.jpeg, createdBy=b5d25455370, createdName=ms1000001786385695, createdTime=Wed Dec 28 20:31:08 CST 2022, time=2022-12-28, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1081922, encodeId=0366108192243, content=偏重的研究方向：肿瘤 经验分享：我的文章13号接收的，回来看评论，很多朋友都在问参考文献格式怎么下，说实话，到现在文章被接收我都不知道哪里下，我当时投稿的时候也是找了半天没找到，后来索性找了个施普林格旗下比较类似的文献格式，然后用endnote编辑成JOCR这个样子的，然后投稿了，到现在接收了也没有什么问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5bc5555629, createdName=解忧, createdTime=Sun Dec 19 22:32:54 CST 2021, time=2021-12-19, status=1, ipAttribution=)]

2022-09-03 cmj544

现在还收SEER挖掘的文章吗？

21 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2124580, encodeId=a9f0212458035, content=可以共同通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7d6401298, createdName=ms2000000538736621, createdTime=Sun Apr 09 13:44:25 CST 2023, time=2023-04-09, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1238888, encodeId=c680123888819, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;生信 经验分享：7.10投稿 7.11修改格式 7.11 再次提交投稿 7.12 分配编辑 7.15 审稿人审稿 8.15 文章接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba432251336, createdName=poppin kitty, createdTime=Mon Aug 15 21:55:12 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103332, encodeId=e9b92103332e5, content=审稿速度:2.0 经验分享：10 reviewers invited 一个月了，可以催稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94318203192, createdName=ms6000001327920543, createdTime=Tue Nov 29 16:42:06 CST 2022, time=2022-11-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1242895, encodeId=c45212428954e, content=现在还收SEER挖掘的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220130/d287bef646804051826c653c20ade5c5/3189bee4394c4a70a2c21f4e2d6b8f13.jpg, createdBy=cb882558554, createdName=cmj544, createdTime=Sat Sep 03 01:41:42 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123298, encodeId=2f2121232987e, content=请教一下大家，大家的审稿人一般都是几个呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=ms1000000056011696, createdTime=Sun Apr 02 18:55:29 CST 2023, time=2023-04-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103169, encodeId=c26a21031699c, content=审稿速度:1.0 经验分享：请问大家接收之后多久见刊的呀？接收之后通讯作者一直没有收到确认proof的通知，一个多月了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf758287370, createdName=ms1000000773147608, createdTime=Mon Nov 28 21:35:40 CST 2022, time=2022-11-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1063656, encodeId=e0ab10636562a, content=昨日凌晨文章接受，因为杂志效率高所以投了，没上5分是个遗憾，写一下时间线吧，贡大家参考 临床回顾研究，头颈肿瘤主编和副编效率一流，审稿人效率也是见过最快的，初审14天，二审7天 2021-8-27 new submission 2021-9-20 minor revisions 2021-10-11 Revision Submitted 2021-10-24 reviews completed 2021-10-24 editor assigned 2021-10-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74db5149632, createdName=1469323em90暂无昵称, createdTime=Mon Oct 25 07:27:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121859, encodeId=e14221218596e, content=请问这个杂志要求查重率在多少以下呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87d45469232, createdName=ms4000000806385083, createdTime=Sun Mar 26 10:34:53 CST 2023, time=2023-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2107899, encodeId=d0cf210e8998b, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：11.10投稿 11.13送审 11.26 2个审稿人接收，1个审稿人意见已回 12.1 第2个审稿人意见回，等待编辑决定 12.7 返修 12.16 提交 12.20 邀请一个审稿人 12.22 收到审稿人报告 12.24 接收 第一次投这个杂志，过程愉快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221012/58d49d92e28d4e819acde854b28c54f3/2d209f1b3c1c49a69e36f6b2ebb7804f.jpeg, createdBy=b5d25455370, createdName=ms1000001786385695, createdTime=Wed Dec 28 20:31:08 CST 2022, time=2022-12-28, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1081922, encodeId=0366108192243, content=偏重的研究方向：肿瘤 经验分享：我的文章13号接收的，回来看评论，很多朋友都在问参考文献格式怎么下，说实话，到现在文章被接收我都不知道哪里下，我当时投稿的时候也是找了半天没找到，后来索性找了个施普林格旗下比较类似的文献格式，然后用endnote编辑成JOCR这个样子的，然后投稿了，到现在接收了也没有什么问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5bc5555629, createdName=解忧, createdTime=Sun Dec 19 22:32:54 CST 2021, time=2021-12-19, status=1, ipAttribution=)]

2023-04-02 ms1000000056011696 来自广东省

请教一下大家，大家的审稿人一般都是几个呀

16 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2124580, encodeId=a9f0212458035, content=可以共同通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7d6401298, createdName=ms2000000538736621, createdTime=Sun Apr 09 13:44:25 CST 2023, time=2023-04-09, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1238888, encodeId=c680123888819, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;生信 经验分享：7.10投稿 7.11修改格式 7.11 再次提交投稿 7.12 分配编辑 7.15 审稿人审稿 8.15 文章接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba432251336, createdName=poppin kitty, createdTime=Mon Aug 15 21:55:12 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103332, encodeId=e9b92103332e5, content=审稿速度:2.0 经验分享：10 reviewers invited 一个月了，可以催稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94318203192, createdName=ms6000001327920543, createdTime=Tue Nov 29 16:42:06 CST 2022, time=2022-11-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1242895, encodeId=c45212428954e, content=现在还收SEER挖掘的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220130/d287bef646804051826c653c20ade5c5/3189bee4394c4a70a2c21f4e2d6b8f13.jpg, createdBy=cb882558554, createdName=cmj544, createdTime=Sat Sep 03 01:41:42 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123298, encodeId=2f2121232987e, content=请教一下大家，大家的审稿人一般都是几个呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=ms1000000056011696, createdTime=Sun Apr 02 18:55:29 CST 2023, time=2023-04-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103169, encodeId=c26a21031699c, content=审稿速度:1.0 经验分享：请问大家接收之后多久见刊的呀？接收之后通讯作者一直没有收到确认proof的通知，一个多月了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf758287370, createdName=ms1000000773147608, createdTime=Mon Nov 28 21:35:40 CST 2022, time=2022-11-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1063656, encodeId=e0ab10636562a, content=昨日凌晨文章接受，因为杂志效率高所以投了，没上5分是个遗憾，写一下时间线吧，贡大家参考 临床回顾研究，头颈肿瘤主编和副编效率一流，审稿人效率也是见过最快的，初审14天，二审7天 2021-8-27 new submission 2021-9-20 minor revisions 2021-10-11 Revision Submitted 2021-10-24 reviews completed 2021-10-24 editor assigned 2021-10-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74db5149632, createdName=1469323em90暂无昵称, createdTime=Mon Oct 25 07:27:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121859, encodeId=e14221218596e, content=请问这个杂志要求查重率在多少以下呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87d45469232, createdName=ms4000000806385083, createdTime=Sun Mar 26 10:34:53 CST 2023, time=2023-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2107899, encodeId=d0cf210e8998b, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：11.10投稿 11.13送审 11.26 2个审稿人接收，1个审稿人意见已回 12.1 第2个审稿人意见回，等待编辑决定 12.7 返修 12.16 提交 12.20 邀请一个审稿人 12.22 收到审稿人报告 12.24 接收 第一次投这个杂志，过程愉快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221012/58d49d92e28d4e819acde854b28c54f3/2d209f1b3c1c49a69e36f6b2ebb7804f.jpeg, createdBy=b5d25455370, createdName=ms1000001786385695, createdTime=Wed Dec 28 20:31:08 CST 2022, time=2022-12-28, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1081922, encodeId=0366108192243, content=偏重的研究方向：肿瘤 经验分享：我的文章13号接收的，回来看评论，很多朋友都在问参考文献格式怎么下，说实话，到现在文章被接收我都不知道哪里下，我当时投稿的时候也是找了半天没找到，后来索性找了个施普林格旗下比较类似的文献格式，然后用endnote编辑成JOCR这个样子的，然后投稿了，到现在接收了也没有什么问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5bc5555629, createdName=解忧, createdTime=Sun Dec 19 22:32:54 CST 2021, time=2021-12-19, status=1, ipAttribution=)]

2022-11-28 ms1000000773147608 来自湖南省

审稿速度:1.0
经验分享：请问大家接收之后多久见刊的呀？接收之后通讯作者一直没有收到确认proof的通知，一个多月了。

24 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2124580, encodeId=a9f0212458035, content=可以共同通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7d6401298, createdName=ms2000000538736621, createdTime=Sun Apr 09 13:44:25 CST 2023, time=2023-04-09, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1238888, encodeId=c680123888819, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;生信 经验分享：7.10投稿 7.11修改格式 7.11 再次提交投稿 7.12 分配编辑 7.15 审稿人审稿 8.15 文章接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba432251336, createdName=poppin kitty, createdTime=Mon Aug 15 21:55:12 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103332, encodeId=e9b92103332e5, content=审稿速度:2.0 经验分享：10 reviewers invited 一个月了，可以催稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94318203192, createdName=ms6000001327920543, createdTime=Tue Nov 29 16:42:06 CST 2022, time=2022-11-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1242895, encodeId=c45212428954e, content=现在还收SEER挖掘的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220130/d287bef646804051826c653c20ade5c5/3189bee4394c4a70a2c21f4e2d6b8f13.jpg, createdBy=cb882558554, createdName=cmj544, createdTime=Sat Sep 03 01:41:42 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123298, encodeId=2f2121232987e, content=请教一下大家，大家的审稿人一般都是几个呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=ms1000000056011696, createdTime=Sun Apr 02 18:55:29 CST 2023, time=2023-04-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103169, encodeId=c26a21031699c, content=审稿速度:1.0 经验分享：请问大家接收之后多久见刊的呀？接收之后通讯作者一直没有收到确认proof的通知，一个多月了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf758287370, createdName=ms1000000773147608, createdTime=Mon Nov 28 21:35:40 CST 2022, time=2022-11-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1063656, encodeId=e0ab10636562a, content=昨日凌晨文章接受，因为杂志效率高所以投了，没上5分是个遗憾，写一下时间线吧，贡大家参考 临床回顾研究，头颈肿瘤主编和副编效率一流，审稿人效率也是见过最快的，初审14天，二审7天 2021-8-27 new submission 2021-9-20 minor revisions 2021-10-11 Revision Submitted 2021-10-24 reviews completed 2021-10-24 editor assigned 2021-10-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74db5149632, createdName=1469323em90暂无昵称, createdTime=Mon Oct 25 07:27:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121859, encodeId=e14221218596e, content=请问这个杂志要求查重率在多少以下呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87d45469232, createdName=ms4000000806385083, createdTime=Sun Mar 26 10:34:53 CST 2023, time=2023-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2107899, encodeId=d0cf210e8998b, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：11.10投稿 11.13送审 11.26 2个审稿人接收，1个审稿人意见已回 12.1 第2个审稿人意见回，等待编辑决定 12.7 返修 12.16 提交 12.20 邀请一个审稿人 12.22 收到审稿人报告 12.24 接收 第一次投这个杂志，过程愉快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221012/58d49d92e28d4e819acde854b28c54f3/2d209f1b3c1c49a69e36f6b2ebb7804f.jpeg, createdBy=b5d25455370, createdName=ms1000001786385695, createdTime=Wed Dec 28 20:31:08 CST 2022, time=2022-12-28, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1081922, encodeId=0366108192243, content=偏重的研究方向：肿瘤 经验分享：我的文章13号接收的，回来看评论，很多朋友都在问参考文献格式怎么下，说实话，到现在文章被接收我都不知道哪里下，我当时投稿的时候也是找了半天没找到，后来索性找了个施普林格旗下比较类似的文献格式，然后用endnote编辑成JOCR这个样子的，然后投稿了，到现在接收了也没有什么问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5bc5555629, createdName=解忧, createdTime=Sun Dec 19 22:32:54 CST 2021, time=2021-12-19, status=1, ipAttribution=)]

2021-10-25 1469323em90暂无昵称

昨日凌晨文章接受，因为杂志效率高所以投了，没上5分是个遗憾，写一下时间线吧，贡大家参考
临床回顾研究，头颈肿瘤主编和副编效率一流，审稿人效率也是见过最快的，初审14天，二审7天
2021-8-27 new submission
2021-9-20 minor revisions
2021-10-11 Revision Submitted
2021-10-24 reviews completed
2021-10-24 editor assigned
2021-10-24 accept

93 23

展开23条回复

[GetPortalCommentsPageByObjectIdResponse(id=2124580, encodeId=a9f0212458035, content=可以共同通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7d6401298, createdName=ms2000000538736621, createdTime=Sun Apr 09 13:44:25 CST 2023, time=2023-04-09, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1238888, encodeId=c680123888819, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;生信 经验分享：7.10投稿 7.11修改格式 7.11 再次提交投稿 7.12 分配编辑 7.15 审稿人审稿 8.15 文章接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba432251336, createdName=poppin kitty, createdTime=Mon Aug 15 21:55:12 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103332, encodeId=e9b92103332e5, content=审稿速度:2.0 经验分享：10 reviewers invited 一个月了，可以催稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94318203192, createdName=ms6000001327920543, createdTime=Tue Nov 29 16:42:06 CST 2022, time=2022-11-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1242895, encodeId=c45212428954e, content=现在还收SEER挖掘的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220130/d287bef646804051826c653c20ade5c5/3189bee4394c4a70a2c21f4e2d6b8f13.jpg, createdBy=cb882558554, createdName=cmj544, createdTime=Sat Sep 03 01:41:42 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123298, encodeId=2f2121232987e, content=请教一下大家，大家的审稿人一般都是几个呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=ms1000000056011696, createdTime=Sun Apr 02 18:55:29 CST 2023, time=2023-04-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103169, encodeId=c26a21031699c, content=审稿速度:1.0 经验分享：请问大家接收之后多久见刊的呀？接收之后通讯作者一直没有收到确认proof的通知，一个多月了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf758287370, createdName=ms1000000773147608, createdTime=Mon Nov 28 21:35:40 CST 2022, time=2022-11-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1063656, encodeId=e0ab10636562a, content=昨日凌晨文章接受，因为杂志效率高所以投了，没上5分是个遗憾，写一下时间线吧，贡大家参考 临床回顾研究，头颈肿瘤主编和副编效率一流，审稿人效率也是见过最快的，初审14天，二审7天 2021-8-27 new submission 2021-9-20 minor revisions 2021-10-11 Revision Submitted 2021-10-24 reviews completed 2021-10-24 editor assigned 2021-10-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74db5149632, createdName=1469323em90暂无昵称, createdTime=Mon Oct 25 07:27:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121859, encodeId=e14221218596e, content=请问这个杂志要求查重率在多少以下呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87d45469232, createdName=ms4000000806385083, createdTime=Sun Mar 26 10:34:53 CST 2023, time=2023-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2107899, encodeId=d0cf210e8998b, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：11.10投稿 11.13送审 11.26 2个审稿人接收，1个审稿人意见已回 12.1 第2个审稿人意见回，等待编辑决定 12.7 返修 12.16 提交 12.20 邀请一个审稿人 12.22 收到审稿人报告 12.24 接收 第一次投这个杂志，过程愉快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221012/58d49d92e28d4e819acde854b28c54f3/2d209f1b3c1c49a69e36f6b2ebb7804f.jpeg, createdBy=b5d25455370, createdName=ms1000001786385695, createdTime=Wed Dec 28 20:31:08 CST 2022, time=2022-12-28, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1081922, encodeId=0366108192243, content=偏重的研究方向：肿瘤 经验分享：我的文章13号接收的，回来看评论，很多朋友都在问参考文献格式怎么下，说实话，到现在文章被接收我都不知道哪里下，我当时投稿的时候也是找了半天没找到，后来索性找了个施普林格旗下比较类似的文献格式，然后用endnote编辑成JOCR这个样子的，然后投稿了，到现在接收了也没有什么问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5bc5555629, createdName=解忧, createdTime=Sun Dec 19 22:32:54 CST 2021, time=2021-12-19, status=1, ipAttribution=)]

2023-03-26 ms4000000806385083 来自浙江省

请问这个杂志要求查重率在多少以下呀？

26 0

[GetPortalCommentsPageByObjectIdResponse(id=2124580, encodeId=a9f0212458035, content=可以共同通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7d6401298, createdName=ms2000000538736621, createdTime=Sun Apr 09 13:44:25 CST 2023, time=2023-04-09, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1238888, encodeId=c680123888819, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;生信 经验分享：7.10投稿 7.11修改格式 7.11 再次提交投稿 7.12 分配编辑 7.15 审稿人审稿 8.15 文章接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba432251336, createdName=poppin kitty, createdTime=Mon Aug 15 21:55:12 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103332, encodeId=e9b92103332e5, content=审稿速度:2.0 经验分享：10 reviewers invited 一个月了，可以催稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94318203192, createdName=ms6000001327920543, createdTime=Tue Nov 29 16:42:06 CST 2022, time=2022-11-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1242895, encodeId=c45212428954e, content=现在还收SEER挖掘的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220130/d287bef646804051826c653c20ade5c5/3189bee4394c4a70a2c21f4e2d6b8f13.jpg, createdBy=cb882558554, createdName=cmj544, createdTime=Sat Sep 03 01:41:42 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123298, encodeId=2f2121232987e, content=请教一下大家，大家的审稿人一般都是几个呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=ms1000000056011696, createdTime=Sun Apr 02 18:55:29 CST 2023, time=2023-04-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103169, encodeId=c26a21031699c, content=审稿速度:1.0 经验分享：请问大家接收之后多久见刊的呀？接收之后通讯作者一直没有收到确认proof的通知，一个多月了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf758287370, createdName=ms1000000773147608, createdTime=Mon Nov 28 21:35:40 CST 2022, time=2022-11-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1063656, encodeId=e0ab10636562a, content=昨日凌晨文章接受，因为杂志效率高所以投了，没上5分是个遗憾，写一下时间线吧，贡大家参考 临床回顾研究，头颈肿瘤主编和副编效率一流，审稿人效率也是见过最快的，初审14天，二审7天 2021-8-27 new submission 2021-9-20 minor revisions 2021-10-11 Revision Submitted 2021-10-24 reviews completed 2021-10-24 editor assigned 2021-10-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74db5149632, createdName=1469323em90暂无昵称, createdTime=Mon Oct 25 07:27:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121859, encodeId=e14221218596e, content=请问这个杂志要求查重率在多少以下呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87d45469232, createdName=ms4000000806385083, createdTime=Sun Mar 26 10:34:53 CST 2023, time=2023-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2107899, encodeId=d0cf210e8998b, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：11.10投稿 11.13送审 11.26 2个审稿人接收，1个审稿人意见已回 12.1 第2个审稿人意见回，等待编辑决定 12.7 返修 12.16 提交 12.20 邀请一个审稿人 12.22 收到审稿人报告 12.24 接收 第一次投这个杂志，过程愉快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221012/58d49d92e28d4e819acde854b28c54f3/2d209f1b3c1c49a69e36f6b2ebb7804f.jpeg, createdBy=b5d25455370, createdName=ms1000001786385695, createdTime=Wed Dec 28 20:31:08 CST 2022, time=2022-12-28, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1081922, encodeId=0366108192243, content=偏重的研究方向：肿瘤 经验分享：我的文章13号接收的，回来看评论，很多朋友都在问参考文献格式怎么下，说实话，到现在文章被接收我都不知道哪里下，我当时投稿的时候也是找了半天没找到，后来索性找了个施普林格旗下比较类似的文献格式，然后用endnote编辑成JOCR这个样子的，然后投稿了，到现在接收了也没有什么问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5bc5555629, createdName=解忧, createdTime=Sun Dec 19 22:32:54 CST 2021, time=2021-12-19, status=1, ipAttribution=)]

2022-12-28 ms1000001786385695 来自甘肃省

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：11.10投稿
11.13送审
11.26 2个审稿人接收，1个审稿人意见已回
12.1 第2个审稿人意见回，等待编辑决定
12.7 返修
12.16 提交
12.20 邀请一个审稿人
12.22 收到审稿人报告
12.24 接收
第一次投这个杂志，过程愉快！

40 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2124580, encodeId=a9f0212458035, content=可以共同通讯吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7d6401298, createdName=ms2000000538736621, createdTime=Sun Apr 09 13:44:25 CST 2023, time=2023-04-09, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1238888, encodeId=c680123888819, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;生信 经验分享：7.10投稿 7.11修改格式 7.11 再次提交投稿 7.12 分配编辑 7.15 审稿人审稿 8.15 文章接收 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba432251336, createdName=poppin kitty, createdTime=Mon Aug 15 21:55:12 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103332, encodeId=e9b92103332e5, content=审稿速度:2.0 经验分享：10 reviewers invited 一个月了，可以催稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94318203192, createdName=ms6000001327920543, createdTime=Tue Nov 29 16:42:06 CST 2022, time=2022-11-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1242895, encodeId=c45212428954e, content=现在还收SEER挖掘的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220130/d287bef646804051826c653c20ade5c5/3189bee4394c4a70a2c21f4e2d6b8f13.jpg, createdBy=cb882558554, createdName=cmj544, createdTime=Sat Sep 03 01:41:42 CST 2022, time=2022-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2123298, encodeId=2f2121232987e, content=请教一下大家，大家的审稿人一般都是几个呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72446462907, createdName=ms1000000056011696, createdTime=Sun Apr 02 18:55:29 CST 2023, time=2023-04-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103169, encodeId=c26a21031699c, content=审稿速度:1.0 经验分享：请问大家接收之后多久见刊的呀？接收之后通讯作者一直没有收到确认proof的通知，一个多月了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf758287370, createdName=ms1000000773147608, createdTime=Mon Nov 28 21:35:40 CST 2022, time=2022-11-28, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1063656, encodeId=e0ab10636562a, content=昨日凌晨文章接受，因为杂志效率高所以投了，没上5分是个遗憾，写一下时间线吧，贡大家参考 临床回顾研究，头颈肿瘤主编和副编效率一流，审稿人效率也是见过最快的，初审14天，二审7天 2021-8-27 new submission 2021-9-20 minor revisions 2021-10-11 Revision Submitted 2021-10-24 reviews completed 2021-10-24 editor assigned 2021-10-24 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74db5149632, createdName=1469323em90暂无昵称, createdTime=Mon Oct 25 07:27:38 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121859, encodeId=e14221218596e, content=请问这个杂志要求查重率在多少以下呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87d45469232, createdName=ms4000000806385083, createdTime=Sun Mar 26 10:34:53 CST 2023, time=2023-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2107899, encodeId=d0cf210e8998b, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：11.10投稿 11.13送审 11.26 2个审稿人接收，1个审稿人意见已回 12.1 第2个审稿人意见回，等待编辑决定 12.7 返修 12.16 提交 12.20 邀请一个审稿人 12.22 收到审稿人报告 12.24 接收 第一次投这个杂志，过程愉快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221012/58d49d92e28d4e819acde854b28c54f3/2d209f1b3c1c49a69e36f6b2ebb7804f.jpeg, createdBy=b5d25455370, createdName=ms1000001786385695, createdTime=Wed Dec 28 20:31:08 CST 2022, time=2022-12-28, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1081922, encodeId=0366108192243, content=偏重的研究方向：肿瘤 经验分享：我的文章13号接收的，回来看评论，很多朋友都在问参考文献格式怎么下，说实话，到现在文章被接收我都不知道哪里下，我当时投稿的时候也是找了半天没找到，后来索性找了个施普林格旗下比较类似的文献格式，然后用endnote编辑成JOCR这个样子的，然后投稿了，到现在接收了也没有什么问题, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=32, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a5bc5555629, createdName=解忧, createdTime=Sun Dec 19 22:32:54 CST 2021, time=2021-12-19, status=1, ipAttribution=)]

2021-12-19 解忧

偏重的研究方向：肿瘤
经验分享：我的文章13号接收的，回来看评论，很多朋友都在问参考文献格式怎么下，说实话，到现在文章被接收我都不知道哪里下，我当时投稿的时候也是找了半天没找到，后来索性找了个施普林格旗下比较类似的文献格式，然后用endnote编辑成JOCR这个样子的，然后投稿了，到现在接收了也没有什么问题

6 32

展开32条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务